Small signals can reveal big answers
Liquid biomarkers offer a powerful and noninvasive window into human biology, capturing dynamic molecular signals in real time from blood, plasma, CSF, saliva, and urine. These protein biomarkers can reflect underlying disease processes, even when present at ultralow concentrations. That’s why ultrasensitive detection is essential.
It enables measurements of biomarkers at true physiological baseline levels.
This level of insight is foundational for:
- Early disease detection
- Longitudinal biomarker monitoring
- Patient stratification
- Therapeutic response tracking
This is where Simoa technology is purpose built to lead.
Why Simoa for Ultrasensitive Liquid Biomarkers?
Simoa is a digital immunoassay platform built to quantify single molecules in liquid samples, providing femtogram-level detection without sacrificing precision or throughput.
In real‑world use, Simoa delivers:
- Consistently high detection rates for low‑abundance biomarkers
- Reproducible precision (<10% CVs) across multisite studies
- Strong correlation to clinical reference methods
- Absolute concentration reporting (pg/mL) suitable for diagnostics
These capabilities have enabled Simoa assays to advance from exploratory research tools into CLIA-validated testing and regulatory diagnostic use.
Ultra Sensitivity Is the Difference Between Detection and Discovery
Platforms lacking sufficient sensitivity often report truncated data, missing values, or relative units that obscure biological meaning. This limits discovery, introduces variability, and slows translation.
Ultrasensitive liquid biomarker platforms change that equation by delivering:
- Consistent detection across all sample types
- Absolute quantification (pg/mL) to establish clinical thresholds and comparability
- High precision (<10% CVs) across sites, time points, and patient cohorts
- Linear detection at the lower limit, where disease biology often emerges
With ultra sensitivity, liquid biomarkers transition from exploratory signals into reliable biological measures enabling discoveries that can be validated, reproduced, and translated. This is when data becomes actionable.
Built for Liquid Biology and Proven in the Clinic
Quanterix supports ultrasensitive liquid biomarker studies across:
- Blood, plasma, serum, and CSF
- Saliva, urine, and dried blood spots
- Neurology, oncology, immunology, cardiology, and infectious disease
With validated assays, open assay development, and access to CLIA‑certified testing through the Quanterix Accelerator Lab, Simoa enables continuity from discovery through diagnostics, without changing platforms or compromising data quality.